未知生产厂商
CT0596 is an allogeneic BCMA-targeted CAR-T cell therapy developed by CARsgen Therapeutics on its proprietary THANK-u Plus platform, under investigation for relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL).
CT0596 is an allogeneic BCMA-targeted CAR-T cell therapy developed by CARsgen Therapeutics on its proprietary THANK-u Plus platform, under investigation for relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL).
CT0596 is an allogeneic BCMA-targeted CAR-T cell therapy developed using CARsgen's proprietary THANK-u Plus™ platform. Through the knockout of genes such as NKG2A, TRAC, and B2M, it is designed to reduce the risk of graft-versus-host disease (GvHD) and host immune rejection; additional gene editing further blocks host natural killer (NK) cell-mediated rejection, aiming to enhance efficacy and safety.
CT0596 is being investigated for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL).
